Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:HYBTNASDAQ:LYRANASDAQ:VVOSOTCMKTS:VYCO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHYBTHeyu Biological Technology$0.14$0.16$0.00▼$3.40$14.15M-17.745,371 shs10 shsLYRALyra Therapeutics$13.38+8.8%$8.98$3.81▼$37.50$16.30M-0.01188,105 shs120,145 shsVVOSVivos Therapeutics$3.37+10.5%$2.52$1.97▼$6.28$17.96M7.02469,179 shs1.44 million shsVYCOVycor Medical$0.13+15.9%$0.12$0.04▼$0.50$3.81M-0.421,361 shs14,500 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHYBTHeyu Biological Technology0.00%+45,566.67%-32.35%-11.61%-31.53%LYRALyra Therapeutics+8.78%+25.28%+204.78%+91.14%+0.22%VVOSVivos Therapeutics+10.49%+35.89%+48.46%+8.36%+54.59%VYCOVycor Medical+15.88%+14.87%+2.88%+103.94%+48.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHYBTHeyu Biological TechnologyN/AN/AN/AN/AN/AN/AN/AN/ALYRALyra Therapeutics2.9436 of 5 stars3.24.00.00.03.31.70.6VVOSVivos Therapeutics1.6029 of 5 stars3.32.00.00.02.20.00.6VYCOVycor MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHYBTHeyu Biological Technology 0.00N/AN/AN/ALYRALyra Therapeutics 2.33Hold$100.00647.38% UpsideVVOSVivos Therapeutics 2.50Moderate Buy$4.8242.93% UpsideVYCOVycor Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VYCO, VVOS, LYRA, and HYBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025VVOSVivos TherapeuticsIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$2.255/20/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/15/2025VVOSVivos TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.60 ➝ $6.204/1/2025VVOSVivos TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHYBTHeyu Biological Technology$80K176.81N/AN/A$0.38 per share0.36LYRALyra Therapeutics$1.53M11.63N/AN/A$8.86 per share1.51VVOSVivos Therapeutics$15.03M1.32N/AN/A$1.35 per share2.50VYCOVycor Medical$1.59M2.78N/AN/A($0.11) per share-1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHYBTHeyu Biological Technology-$270KN/A0.00∞N/A-453.55%-6.43%-4.43%N/ALYRALyra Therapeutics-$93.43M-$60.50N/AN/AN/A-6,711.39%-295.52%-66.95%8/13/2025 (Estimated)VVOSVivos Therapeutics-$11.14M-$1.73N/AN/AN/A-76.82%-170.43%-77.82%8/13/2025 (Estimated)VYCOVycor Medical-$110KN/A0.00∞N/A-6.86%N/A-11.44%8/11/2025 (Estimated)Latest VYCO, VVOS, LYRA, and HYBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025VVOSVivos Therapeutics-$0.44-$0.45-$0.01-$0.45$3.63 million$3.70 million5/15/2025Q1 2025VYCOVycor MedicalN/A-$0.01N/A-$0.01N/A$0.44 million5/6/2025Q1 2025LYRALyra Therapeutics-$7.50-$6.00+$1.50-$0.13$0.16 million$0.18 million3/27/2025Q4 2024VVOSVivos Therapeutics-$0.43-$0.28+$0.15-$0.28$3.89 million$3.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHYBTHeyu Biological TechnologyN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/AVYCOVycor MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHYBTHeyu Biological TechnologyN/A0.350.34LYRALyra TherapeuticsN/A2.962.96VVOSVivos TherapeuticsN/A0.770.77VYCOVycor MedicalN/A0.130.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHYBTHeyu Biological TechnologyN/ALYRALyra Therapeutics95.62%VVOSVivos Therapeutics26.35%VYCOVycor MedicalN/AInsider OwnershipCompanyInsider OwnershipHYBTHeyu Biological Technology89.24%LYRALyra Therapeutics3.25%VVOSVivos Therapeutics3.00%VYCOVycor Medical7.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHYBTHeyu Biological Technology6103.25 million11.11 millionNot OptionableLYRALyra Therapeutics501.33 million1.28 millionOptionableVVOSVivos Therapeutics1605.89 million5.71 millionOptionableVYCOVycor Medical633.42 million31.07 millionNot OptionableVYCO, VVOS, LYRA, and HYBT HeadlinesRecent News About These CompaniesVYCO Vycor Medical, Inc.May 31, 2025 | seekingalpha.comVycor Medical Joins B2i Digital Venture Company Program to Build and Educate Its Investor BaseMarch 14, 2025 | finance.yahoo.comEQS-News: Vycor Medical Joins B2i Digital Venture Company Program to Build and Educate Its Investor BaseMarch 13, 2025 | markets.businessinsider.comMedical ethics articles from across Nature PortfolioOctober 22, 2024 | nature.comNBlueChew Review 2024January 17, 2024 | medicalnewstoday.comMWhat to know about bleeding hemorrhoidsDecember 19, 2023 | medicalnewstoday.comMCommon symptoms of depression: What to knowOctober 11, 2023 | medicalnewstoday.comMVycor Medical, Inc. (VYCO)January 7, 2023 | finance.yahoo.comMedical Review BoardNovember 1, 2022 | health.usnews.comMedical Scholars ProgramSeptember 12, 2022 | slu.eduSVycor Medical IncSeptember 8, 2022 | reuters.comMinnetronix commercializes its own product: a minimally invasive deep brain access portAugust 20, 2022 | medcitynews.comMViewSite Brain Access System (VBAS) for the surgical management of deep brain lesionsMay 11, 2022 | nice.org.ukNVycor Medical Year to Date Total Returns (Daily)January 2, 2022 | ycharts.comYVycor Medical Inc (VYCO)December 17, 2021 | nasdaq.comThe journal of physical chemistry. BOctober 18, 2021 | medscape.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYCO, VVOS, LYRA, and HYBT Company DescriptionsHeyu Biological Technology OTCMKTS:HYBT$0.14 0.00 (0.00%) As of 06/25/2025Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.Lyra Therapeutics NASDAQ:LYRA$13.38 +1.08 (+8.78%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$14.44 +1.06 (+7.92%) As of 04:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Vivos Therapeutics NASDAQ:VVOS$3.37 +0.32 (+10.49%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$3.47 +0.10 (+2.94%) As of 04:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.Vycor Medical OTCMKTS:VYCO$0.13 +0.02 (+15.88%) As of 06/26/2025 12:55 PM EasternVycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement which grants for the license to provide NovaVision's products and therapies to patients and professionals in Germany, Austria and Switzerland. It primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
